Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 15, 2026, 1:32 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 673–696 of 1,069 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Placebo (Cohort 3) Clear all
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Sutezolid

NCT03199313
View directory record Official record
Conditions
Tuberculosis, Tuberculosis, Pulmonary
Interventions
Sutezolid, Placebo
Drug
Lead sponsor
Global Alliance for TB Drug Development
Other
Eligibility
19 Years to 50 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Feb 8, 2018 · Synced Oct 15, 2026, 1:32 PM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

A First in Human Single Ascending Dose (SAD) Study of ATI-1013 in Healthy Smokers

NCT07215923
View directory record Official record
Conditions
Thromboangiitis Obliterans (Buerger's Disease)
Interventions
ATI-1013 (0.2 g), ATI-1013 (0.8 g), ATI-1013 (3.2 g), Placebo
Biological · Other
Lead sponsor
Antidote Therapeutics, Inc
Industry
Eligibility
23 Years to 59 Years
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Oct 15, 2025 · Synced Oct 15, 2026, 1:32 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Investigate the Safety and Pharmacokinetics of AZD6793 in Healthy Japanese and Chinese Participants

NCT06368440
View directory record Official record
Conditions
Healthy Participants
Interventions
AZD6793, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 55 Years
Enrollment
39 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024
U.S. locations
1
States / cities
Glendale, California
Source: ClinicalTrials.gov public record
Updated Oct 24, 2025 · Synced Oct 15, 2026, 1:32 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Phase 1, Randomized, Double-Blind, Placebo-controlled Study to Evaluate the Safety and Tolerability of an Enterovirus D68-specific Monoclonal Antibody in Healthy Adults

NCT06444048
View directory record Official record
Conditions
Enterovirus Infection
Interventions
EV68-228-N, Placebo for EV68-228-N
Biological · Other
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 49 Years
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
2
States / cities
Baltimore, Maryland • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated May 4, 2026 · Synced Oct 15, 2026, 1:32 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Multiple Dose Study Of PF-04620110 In Overweight And Obese, Otherwise Healthy Volunteers

NCT00959426
View directory record Official record
Conditions
Obesity, Overweight, Healthy
Interventions
PF-04620110, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years
Enrollment
71 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2010
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jun 7, 2010 · Synced Oct 15, 2026, 1:32 PM EDT
Recruiting Phase 1Phase 2 Interventional Accepts healthy volunteers

Study of XmAb942 in Healthy Participants and Participants With Ulcerative Colitis

NCT06619990
View directory record Official record
Conditions
Ulcerative Colitis (UC)
Interventions
XmAb942, Placebo
Biological · Drug
Lead sponsor
Xencor, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
270 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2030
U.S. locations
30
States / cities
Scottsdale, Arizona • Palo Alto, California • Bradenton, Florida + 25 more
Source: ClinicalTrials.gov public record
Updated Sep 29, 2026 · Synced Oct 15, 2026, 1:32 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Phase 2 Study of Rivaroxaban Reversal by Ciraparantag as Measured by WBCT

NCT03172910
View directory record Official record
Conditions
Healthy
Interventions
Ciraparantag, Placebo, Rivaroxaban
Drug
Lead sponsor
Perosphere Pharmaceuticals Inc, a wholly owned subsidiary of AMAG Pharmaceuticals, Inc.
Industry
Eligibility
50 Years to 75 Years
Enrollment
69 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2019
U.S. locations
1
States / cities
Secaucus, New Jersey
Source: ClinicalTrials.gov public record
Updated Sep 2, 2025 · Synced Oct 15, 2026, 1:32 PM EDT
Recruiting Phase 1 Interventional

Study of ALV-100 to Assess Safety, Tolerability, and PK/PD in Overweight/Obese Participants With or Without T2D

NCT07399678
View directory record Official record
Conditions
Overweight or Obese Adults, Overweight or Obese, Type 2 Diabetes
Interventions
ALV-100, Placebo
Drug
Lead sponsor
Alveus Therapeutics, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
3
States / cities
Miami, Florida • Columbus, Ohio • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Sep 28, 2026 · Synced Oct 15, 2026, 1:32 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study Evaluating the Safety and Efficacy of Topical BPR277 for the Treatment of Atopic Dermatitis and Netherton Syndrome

NCT01428297
View directory record Official record
Conditions
Healthy Volunteers, Atopic Dermatitis, Netherton Syndrome
Interventions
BPR277 ointment (controlled application), Placebo (Vehicle), BPR277 ointment, BPR277
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 65 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2014
U.S. locations
3
States / cities
New Haven, Connecticut • St Louis, Missouri • Fargo, North Dakota
Source: ClinicalTrials.gov public record
Updated Dec 8, 2020 · Synced Oct 15, 2026, 1:32 PM EDT
Completed Phase 1 Interventional

Evaluate the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of BGM0504 Tablets in Non-diabetic Overweight or Obese Adult Subjects

NCT07166081
View directory record Official record
Conditions
Non-diabetic Overweight or Obese
Interventions
BGM0504, Placebo
Drug
Lead sponsor
BrightGene Bio-Medical Technology Co., Ltd.
Industry
Eligibility
18 Years to 65 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 15, 2026 · Synced Oct 15, 2026, 1:32 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Single and Multiple Rising Dose Study of Safety and PK of Metyrapone/Oxazepam Combination (EMB-001)

NCT02406066
View directory record Official record
Conditions
Cocaine Use Disorder, Tobacco Use Disorder
Interventions
metyrapone & oxazepam, Placebo
Drug
Lead sponsor
Embera NeuroTherapeutics, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
2
States / cities
Long Beach, California • Baton Rouge, Louisiana
Source: ClinicalTrials.gov public record
Updated Jul 22, 2016 · Synced Oct 15, 2026, 1:32 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Phase 1, Single-Ascending-Dose, Safety, Tolerability, Pharmacokinetic(PK), and Pharmacodynamic(PD) Study of BIIB068 in Healthy Participants

NCT02829541
View directory record Official record
Conditions
Systemic Lupos Erythematosus, SLE
Interventions
BIIB068, Placebo
Drug
Lead sponsor
Biogen
Industry
Eligibility
18 Years to 55 Years
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016
U.S. locations
1
States / cities
Evansville, Indiana
Source: ClinicalTrials.gov public record
Updated Mar 15, 2017 · Synced Oct 15, 2026, 1:32 PM EDT
Completed Phase 1Phase 2 Interventional

A Phase 1/2 Study to Assess MultiStem® Therapy in Acute Respiratory Distress Syndrome

NCT02611609
View directory record Official record
Conditions
Acute Respiratory Distress Syndrome
Interventions
MultiStem, Placebo
Biological
Lead sponsor
Healios K.K.
Industry
Eligibility
18 Years to 90 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
3
States / cities
Cleveland, Ohio • Philadelphia, Pennsylvania • Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 20, 2019 · Synced Oct 15, 2026, 1:32 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Singe Dose, First in Human Study of PF- 06946860 in Healthy Adult Subjects

NCT03599063
View directory record Official record
Conditions
Healthy
Interventions
PF-06946860, Placebo
Biological · Other
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years
Enrollment
63 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Nov 8, 2019 · Synced Oct 15, 2026, 1:32 PM EDT
Recruiting Phase 1Phase 2 Interventional Accepts healthy volunteers

A Study to Evaluate BMS-986470 in Healthy Volunteers and Participants With Sickle Cell Disease

NCT06481306
View directory record Official record
Conditions
Anemia, Sickle Cell, Healthy Volunteers
Interventions
BMS-986470, Placebo, Famotidine, Pantoprazole
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
224 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2027
U.S. locations
19
States / cities
Birmingham, Alabama • La Jolla, California • Oakland, California + 14 more
Source: ClinicalTrials.gov public record
Updated Aug 18, 2026 · Synced Oct 15, 2026, 1:32 PM EDT
Completed Phase 1Phase 2 Interventional Results available

A Study in Metastatic Cancer and Advanced or Metastatic Unresectable Pancreatic Cancer

NCT01373164
View directory record Official record
Conditions
Neoplasms, Neoplasm Metastasis, Pancreatic Cancer
Interventions
Galunisertib, Gemcitabine, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
170 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
3
States / cities
Tampa, Florida • Harvey, Illinois • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated May 16, 2018 · Synced Oct 15, 2026, 1:32 PM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

A Study of Eloralintide (LY3841136) in Participants With Obesity or Overweight

NCT07738614
View directory record Official record
Conditions
Obesity, Overweight
Interventions
Eloralintide, Placebo, Acetaminophen
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 65 Years
Enrollment
56 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Aug 20, 2026 · Synced Oct 15, 2026, 1:32 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Assessment of Abuse Potential of Rapastinel in Humans

NCT03799900
View directory record Official record
Conditions
Human Abuse Potential
Interventions
Rapastinel, Ketamine, Placebo
Drug
Lead sponsor
Naurex, Inc, an affiliate of Allergan plc
Industry
Eligibility
18 Years to 55 Years
Enrollment
72 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated May 16, 2019 · Synced Oct 15, 2026, 1:32 PM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

A Study of TAK-781 in Healthy Volunteers and in Participants With Non-Cirrhotic Primary Sclerosing Cholangitis (PSC)

NCT07229911
View directory record Official record
Conditions
Healthy Volunteers, Primary Sclerosing Cholangitis
Interventions
TAK-781, Placebo
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 68 Years
Enrollment
134 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2028
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Mar 5, 2026 · Synced Oct 15, 2026, 1:32 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Phase 1 Safety and PK Study of OLT1177 Capsules

NCT02134964
View directory record Official record
Conditions
Healthy Volunteers
Interventions
OLT1177 Capsules, Placebo Capsules
Drug
Lead sponsor
Olatec Therapeutics, Inc.
Industry
Eligibility
18 Years to 60 Years
Enrollment
35 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
College Station, Texas
Source: ClinicalTrials.gov public record
Updated Mar 6, 2015 · Synced Oct 15, 2026, 1:32 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AZD5718 After Single and Multiple Ascending Dose Administration to Healthy Japanese Men

NCT03400488
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
AZD5718 oral suspension, Placebo matching AZD5817 oral suspension
Drug · Other
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 50 Years · Male only
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
1
States / cities
Glendale, California
Source: ClinicalTrials.gov public record
Updated Jun 15, 2018 · Synced Oct 15, 2026, 1:32 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Phase 1 TAK-041 First-in-Human Safety, Tolerability, and Pharmacokinetics Study

NCT02748694
View directory record Official record
Conditions
Healthy Volunteers, Schizophrenia
Interventions
TAK-041, TAK-041 Placebo
Drug
Lead sponsor
Neurocrine Biosciences
Industry
Eligibility
18 Years to 55 Years
Enrollment
114 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2019
U.S. locations
1
States / cities
Glendale, California
Source: ClinicalTrials.gov public record
Updated Mar 19, 2021 · Synced Oct 15, 2026, 1:32 PM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

A Study to Test the Effects of Nezavist at Different Doses in Healthy Adults

NCT06633562
View directory record Official record
Conditions
Healthy, Safety Evaluation of Escalating Doses, Tolerability
Interventions
Nezavist SDD, Placebo
Drug
Lead sponsor
Lohocla Research Corporation
Industry
Eligibility
18 Years to 55 Years
Enrollment
29 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Sep 8, 2026 · Synced Oct 15, 2026, 1:32 PM EDT
Not yet recruiting Phase 1 Interventional Accepts healthy volunteers

Safety and Immunogenicity of Chimeric Hemagglutinin mRNA Vaccine Candidates

NCT07703514
View directory record Official record
Conditions
Influenza
Interventions
cH15/3, cH4/3, cH5/1N1, cH8/1N1, Saline
Biological · Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 59 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 9, 2026 · Synced Oct 15, 2026, 1:32 PM EDT